Andere talen Takeda Pharmaceutical Company Limited

Aandelen

4502

JP3463000004

Farmaceutische producten

Beurs gesloten - Japan Exchange Andere beurzen 07:30:00 21-03-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4.552,00 ^JPY	+0,31%		+2,71%	+8,87%

13/03	De tarieven en dreigende handelsacties van Trump	RE
13/03	Japanse vakbondsgroep zegt flinke gemiddelde 2025 loonsverhoging te hebben gekregen, zij het minder dan vorig jaar	RE

Andere talen

Trump's tariffs and threatened trade actions	13/03
Japan union group says gained hefty average 2025 pay hike, albeit less than last year	13/03
Japan union group says gained hefty average 2025 pay hike, albeit less than last year	13/03
Major Japan union group says agreements struck for average 5.37% pay hike	13/03
Takeda Says Approval Of Glassia (Alpha-1 Proteinase Inhibitor) 4- & 5-Gram Vial Sizes	11/03
Trump's tariffs and threatened trade actions	06/03
Japan's top labour union body says its members seek 6.11% average wage hike	05/03
Croda International Plc Announces Retirement of Julie Kim from the Board, Effective July 26, 2025	03/03
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera	03/03
Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide	03/03
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera	03/03
Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera	03/03
Takeda Pharmaceutical : Provides Update on Status of Acquisition of Own Shares (Pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan)	03/03
European Panel Backs Approval of Topical Gene Therapy, Three Other New Medicines	28/02
All of Trump's tariffs and threatened trade actions	26/02
Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug	24/02
All of Donald Trump's tariffs and threatened trade actions	19/02
Takeda Pharma Has Halted Joint Development Of Rare Disease Treatment Using Nucleic Acid Technology, Nikkei Says	18/02
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX in Combination with Opdivo in Patients with Advanced Kidney Cancer at ASCO GU 2025	17/02
All of Donald Trump's tariffs and threatened trade actions	10/02
Bain Capital to Buy Mitsubishi Chemical's Pharma Business for More Than $3 Billion -- Update	07/02
Takeda Delivers Strong Third-Quarter FY2024 Results, Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth	31/01
Takeda Pharmaceutical's Profit Up Nearly 44% in Nine-Month Period	31/01
Japon: une femme prend la tête du géant pharmaceutique Takeda	31/01
Takeda Pharmaceutical Ends Soticlestat Development After Failed Trials	31/01

e8105a30f49780a2e628bb5e.l1mlE6HQcCTtUsC22_YsPJxR9wu87DCnON8vxrK5aUY.1Qn2XfLpHl28ZK7DoaZYTM4-hWrkowPAafJ5pd7dXTGnGOF29-k1aLs1rw

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Takeda CEO Weber over medicijnpijplijn, geopolitieke risico's

13 januari 2025 om 21:45 uur